NC
XENE icon

nVerses Capital’s Xenon Pharmaceuticals XENE Stock Holding History

nVerses Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,600
Closed -$102K – 913
2024
Q3 		$102K Buy
+2,600
New +$105K 0.05% 477

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

nVerses Capital's XENE Position: Q4 2024 in Review

nVerses Capital sold out of Xenon Pharmaceuticals (XENE) in Q4 2024, closing a stake of 2,600 shares — an estimated $102K sold.

nVerses Capital first reported a position in XENE in Q3 2024 and held it in 1 quarter. The position peaked at $102K in Q3 2024. 209 funds tracked by Wall St. Rank hold XENE as of Q4 2024.

  • nVerses Capital reported no remaining Xenon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 2,600 Xenon Pharmaceuticals shares in Q4 2024, an estimated $102K.
  • nVerses Capital first reported a position in Xenon Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Xenon Pharmaceuticals position peaked at $102K in Q3 2024.
  • 209 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.